Are Wall Street Analysts Predicting GE HealthCare Stock Will Climb or Sink?

Headquartered in Chicago, Illinois, GE HealthCare Technologies Inc. (GEHC) is a leading global healthcare technology company that provides medical technology, pharmaceutical diagnostics, digital solutions, services, and data analytics to improve healthcare efficiency, precision, and patient outcomes. It has a market capitalization of $32.4 billion.

Shares of this leading healthcare technology company have underperformed the broader market over the past year. GEHC has gained marginally over this period, while the broader S&P 500 Index ($SPX) has climbed nearly 22.4%. The stock has considerably underperformed the index in 2026, declining 12.5% year-to-date, compared with the S&P 500’s 13.3% gain over the same period.

The stock has outpaced the U.S. Medical Devices ETF (IHI), which has declined 10.3% over the past year. On a year-to-date basis, GEHC has performed in line with IHI, with both declining 12.5%.

On July 29, GE HealthCare reported its Q2 FY2026 earnings, sending its shares up about 12.2% as results topped expectations and the company reaffirmed guidance. Revenues grew 5.7% to $5.3 billion, driven by Pharmaceutical Diagnostics and Advanced Imaging Solutions, while Patient Care Solutions revenue fell 13.3%. Adjusted EPS rose 6.6% to $1.13, aided by tariff refunds and a lower tax rate, with total orders up 11.1% organically and a record backlog of $23.90 billion.

GE HealthCare reaffirmed its full-year 2026 guidance, including organic revenue growth of 3% to 4%, adjusted EBIT margin of 15.4% to 15.7%, and adjusted EPS of $4.80 to $5, representing 4.6% to 9% growth. The company also continues to expect free cash flow of approximately $1.6 billion. 

Analysts expect GEHC’s diluted EPS to rise 7.4% year-over-year to $4.93 for the fiscal year ending in December 2026. However, GEHC has surpassed consensus EPS estimates in three of the past four quarters, while missing in the remaining quarter.

Based on the 21 analysts covering GEHC stock, the consensus rating is a “Moderate Buy.” The rating is based on 11 “Strong Buy” ratings, two “Moderate Buy” ratings, seven “Hold” ratings, and one “Strong Sell” rating.

This configuration has been consistent over the past few months.

On July 31, UBS analyst Graham Doyle maintained a “Hold” rating on GE HealthCare and raised the price target to $73 from $67.

Based on analysts' estimates, the mean price target of $81.23 implies a 13.2% premium to GEHC's current share price. The Street-high price target of $100 implies a 39.3% upside.